---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107320"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:44:49.113659+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials

## Summary
- ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.
- ARD-201 attenuated weight regain after tirzepatide withdrawal; combo with low-dose tirzepatide outperformed high-dose tirzepatide alone.
- Phase 2 POWER trial (2H 2025) targets weight regain prevention in patients discontinuing GLP-1RA therapy.
- Phase 2 STRENGTH trial (1H 2026) to test monotherapy and combination with GLP-1RA, replacing prior EMPOWER trial.

## SEC filing metadata
- accession: 0000950170-25-107320
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/0000950170-25-107320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/ck0001774857-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107320
- JSON: https://secwatch.observer/filing/0000950170-25-107320.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.